Arcturus Therapeutics Holdings Inc

NASDAQ:ARCT   3:59:53 PM EDT
45.19
+0.68 (+1.53%)
4:51:57 PM EDT: $44.93 -0.26 (-0.58%)
Products, Regulatory

Arcturus Therapeutics Announces Approval From Vietnam Ministry Of Health To Proceed Into Phase 3B Study For ARCT-154

Published: 10/12/2021 13:18 GMT
Arcturus Therapeutics Holdings Inc (ARCT) - Arcturus Therapeutics Announces Approval From Vietnam Ministry of Health to Proceed Into Phase 3b Study for Arct-154, a Next Generation Starr™ Mrna Vaccine Targeting Sars-cov-2 Delta Variant and Other Variants of Concern.
Arcturus Therapeutics Holdings Inc - Phase 3b Dosing of Arct-154 Initiated.
Arcturus Therapeutics Holdings Inc - Initiation of Phase 3b Study Follows Review of Safety Data From Initial 1,000 Phase 1/2/3a Participants.
Arcturus Therapeutics Holdings Inc - Arct-154 Remains on Track for Emergency Use Authorization (eua) Filing in December 2021.
Arcturus Therapeutics Holdings - Approval to Proceed With Phase 3b Portion of Study.